ProstaLund AB (PLUN) AI Stock Analysis

• Market Cap: kr2.30M
• Dividend Yield: N/A
• Average Volume (3M): 92.84K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.48
• Revenue Growth: -30.56%
• EPS Growth: 7.17%
• Country: SE
• Employees: 9
• Sector: Healthcare
• Sector Strength: 37
• Industry: Medical - Care Facilities
• EPS (TTM): -1.39
• Shares Outstanding: 3,624,052
• 10 Day Avg. Volume: 181,700
• 30 Day Avg. Volume: 92,839
• PEG Ratio: <0.01
• Price to Book (P/B): 0.07
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.12
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: kr1.01
• Price Target Upside: 57.17% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 40 Underperform
• Price Target: kr0.50 ▼(-21.88%Downside)

ProstaLund AB's overall score is impacted primarily by its financial performance challenges, including negative profit margins and cash flow issues. Technical analysis confirms bearish momentum, and valuation metrics reflect lack of profitability. The absence of earnings call and corporate events data limits further insights.

ProstaLund AB Business Overview & Revenue Model

Company Description

ProstaLund AB (PLUN) is a Swedish medical technology company specializing in innovative solutions for the treatment of benign prostatic hyperplasia (BPH), a common condition that affects the prostate gland in men. The company's core product, CoreTherm, is a minimally invasive treatment that uses localized heat therapy to alleviate symptoms of BPH, offering an alternative to traditional surgical methods.

How the Company Makes Money

ProstaLund AB generates revenue primarily through the sale and distribution of its CoreTherm system to hospitals, clinics, and healthcare providers worldwide. The company also earns income from service contracts, maintenance agreements, and the sale of consumables and accessories associated with the CoreTherm system. ProstaLund may engage in partnerships with healthcare organizations and distributors to expand its market reach and enhance its sales channels, contributing to its overall earnings.

ProstaLund AB Financial Statement Overview

Summary

ProstaLund AB faces challenges with declining revenues and persistent losses impacting both profitability and cash flow. While the balance sheet remains relatively stable, cash flow issues and negative earnings signal potential financial instability if not addressed.

Income Statement

ProstaLund AB shows a declining revenue trend with significant negative EBIT and net income over the past years, indicating operational inefficiencies. The gross profit margin is positive but overshadowed by increasing operating losses, affecting overall profitability.

Balance Sheet

The company maintains a solid equity base with manageable debt levels, as reflected in a low debt-to-equity ratio. However, the consistent net losses are eroding equity, posing risks if the trend persists.

Cash Flow

Negative operating and free cash flows highlight cash burn issues, indicating ProstaLund AB is relying heavily on financing activities to sustain operations. The inability to generate positive cash flow from operations is concerning for long-term sustainability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	13.97M	13.72M	22.21M	17.41M	17.07M	12.46M
Gross Profit	9.21M	8.87M	15.65M	12.87M	14.68M	9.54M
EBITDA	-22.70M	-22.45M	-16.57M	-10.67M	-7.54M	-9.75M
Net Income	-22.91M	-22.63M	-17.01M	-11.30M	-7.92M	-10.04M
Balance Sheet
Total Assets	56.23M	61.64M	65.51M	51.04M	43.48M	30.84M
Cash, Cash Equivalents and Short-Term Investments	2.39M	7.82M	15.35M	12.28M	13.24M	10.49M
Total Debt	833.00K	933.00K	1.33M	1.73M	200.00K	600.00K
Total Liabilities	6.16M	6.46M	10.22M	9.36M	8.02M	5.49M
Stockholders Equity	50.07M	55.18M	55.29M	41.69M	35.46M	25.35M
Cash Flow
Free Cash Flow	-26.85M	-29.58M	-27.06M	-20.96M	-14.99M	-12.05M
Operating Cash Flow	-20.13M	-22.59M	-23.80M	-16.20M	-5.80M	-8.58M
Investing Cash Flow	-6.72M	-6.99M	-3.35M	-4.75M	-9.19M	-3.47M
Financing Cash Flow	22.30M	22.37M	30.22M	19.99M	17.73M	12.79M

ProstaLund AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.64
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:PLUN, the sentiment is Negative. The current price of 0.64 is below the 20-day moving average (MA) of 1.13, below the 50-day MA of 2.30, and below the 200-day MA of 7.37, indicating a bearish trend. The MACD of -0.33 indicates Negative momentum. The RSI at 30.31 is Neutral, neither overbought nor oversold. The STOCH value of 7.65 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:PLUN.

ProstaLund AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CMOTEC.B	54 Neutral	kr49.02M	―	-236.60%	―	132.67%	58.89%
Sector *	52 Neutral	kr5.53B	11.11	-72.81%	1.94%	25.71%	21.63%
PLUN	40 Underperform	kr2.30M	―	-44.57%	―	-30.56%	7.17%
LIDDS	37 Underperform	kr12.25M	―	-107.11%	―	―	94.98%
PROGEN	35 Underperform	kr35.89M	―	-139.61%	―	-85.32%	92.64%
ACTI	32 Underperform	kr290.32M	―	-186.40%	―	―	24.47%